

European Consortium develops innovative test to predict the COVID-19 impact in the heart



A team led by CNC group leader Lino Ferreira integrates an European research consortium which seeks to develop a new diagnostic test to identify COVID-19 patients that may be prone to develop fatal cardiovascular complications.

Named "COVIRNA – A diagnostic test to ameliorate the surveillance and treatment of COVID-19 patients", the project has a duration of 2 years, and has a 3.9 million euros worth of financing from the European Union, within the action plan ERAvsCorona, which promotes the cooperation between European research institutions to strengthen the pandemic response.

Know more here: https://noticias.uc.pt/universo-uc/consorcio-europeu-desenvolve-teste-inovador-para-prever-o-impacto-da-covid-19-no-coracao/

News:

Diário de Coimbra | December 22 (<u>see here</u>) Bairrada Informação Online | December 22 (<u>see here</u>)

T+351 231 249 170